These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29242210)

  • 1. Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophy.
    Benedetti S; Uno N; Hoshiya H; Ragazzi M; Ferrari G; Kazuki Y; Moyle LA; Tonlorenzi R; Lombardo A; Chaouch S; Mouly V; Moore M; Popplewell L; Kazuki K; Katoh M; Naldini L; Dickson G; Messina G; Oshimura M; Cossu G; Tedesco FS
    EMBO Mol Med; 2018 Feb; 10(2):254-275. PubMed ID: 29242210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy.
    Tedesco FS; Hoshiya H; D'Antona G; Gerli MF; Messina G; Antonini S; Tonlorenzi R; Benedetti S; Berghella L; Torrente Y; Kazuki Y; Bottinelli R; Oshimura M; Cossu G
    Sci Transl Med; 2011 Aug; 3(96):96ra78. PubMed ID: 21849666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Challenge toward gene-therapy using iPS cells for Duchenne muscular dystrophy].
    Oshimura M; Kazuki Y; Uno N
    Rinsho Shinkeigaku; 2012; 52(11):1139-42. PubMed ID: 23196542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete genetic correction of ips cells from Duchenne muscular dystrophy.
    Kazuki Y; Hiratsuka M; Takiguchi M; Osaki M; Kajitani N; Hoshiya H; Hiramatsu K; Yoshino T; Kazuki K; Ishihara C; Takehara S; Higaki K; Nakagawa M; Takahashi K; Yamanaka S; Oshimura M
    Mol Ther; 2010 Feb; 18(2):386-93. PubMed ID: 19997091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous Cell Therapy Approach for Duchenne Muscular Dystrophy using PiggyBac Transposons and Mesoangioblasts.
    Iyer PS; Mavoungou LO; Ronzoni F; Zemla J; Schmid-Siegert E; Antonini S; Neff LA; Dorchies OM; Jaconi M; Lekka M; Messina G; Mermod N
    Mol Ther; 2018 Apr; 26(4):1093-1108. PubMed ID: 29503200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene.
    Hoshiya H; Kazuki Y; Abe S; Takiguchi M; Kajitani N; Watanabe Y; Yoshino T; Shirayoshi Y; Higaki K; Messina G; Cossu G; Oshimura M
    Mol Ther; 2009 Feb; 17(2):309-17. PubMed ID: 19034264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length human dystrophin on human artificial chromosome compensates for mouse dystrophin deficiency in a Duchenne muscular dystrophy mouse model.
    Hiramuki Y; Abe S; Uno N; Kazuki K; Takata S; Miyamoto H; Takayama H; Morimoto K; Takehara S; Osaki M; Tanihata J; Takeda S; Tomizuka K; Oshimura M; Kazuki Y
    Sci Rep; 2023 Mar; 13(1):4360. PubMed ID: 36928364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy.
    He R; Li H; Wang L; Li Y; Zhang Y; Chen M; Zhu Y; Zhang C
    Biol Res; 2020 May; 53(1):22. PubMed ID: 32430065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-Based Dystrophin Restoration Reveals a Novel Role for Dystrophin in Bioenergetics and Stress Resistance of Muscle Progenitors.
    Matre PR; Mu X; Wu J; Danila D; Hall MA; Kolonin MG; Darabi R; Huard J
    Stem Cells; 2019 Dec; 37(12):1615-1628. PubMed ID: 31574188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of Functional Full-Length Dystrophin After Intramuscular Transplantation of Foamy Virus-Transduced Myoblasts.
    Meng J; Sweeney NP; Doreste B; Muntoni F; McClure M; Morgan J
    Hum Gene Ther; 2020 Feb; 31(3-4):241-252. PubMed ID: 31801386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy.
    Meng J; Counsell JR; Reza M; Laval SH; Danos O; Thrasher A; Lochmüller H; Muntoni F; Morgan JE
    Sci Rep; 2016 Jan; 6():19750. PubMed ID: 26813695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Mini-Dystrophin on Dystrophin-Deficient, Human Skeletal Muscle-Derived Cells.
    Meng J; Counsell J; Morgan JE
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DYS-HAC-iPS cells: the combination of gene and cell therapy to treat duchenne muscular dystrophy.
    Park IH
    Mol Ther; 2010 Feb; 18(2):238-40. PubMed ID: 20125163
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of CCAAT/Enhancer-Binding Protein β Expression With the Phosphodiesterase Inhibitor Isobutylmethylxanthine Improves Myoblast Engraftment Into Dystrophic Muscle.
    Lala-Tabbert N; Fu D; Wiper-Bergeron N
    Stem Cells Transl Med; 2016 Apr; 5(4):500-10. PubMed ID: 26941360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells.
    Chaouch S; Mouly V; Goyenvalle A; Vulin A; Mamchaoui K; Negroni E; Di Santo J; Butler-Browne G; Torrente Y; Garcia L; Furling D
    Hum Gene Ther; 2009 Jul; 20(7):784-90. PubMed ID: 19358679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
    Domenig SA; Bundschuh N; Lenardič A; Ghosh A; Kim I; Qabrati X; D'Hulst G; Bar-Nur O
    Stem Cell Reports; 2022 Feb; 17(2):321-336. PubMed ID: 34995499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
    Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
    Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.